CXCR1 and neoplasm: The latter results show that the blockage of CXCR1-signalling in tumorspheres not only directly reduces the proliferation and invasiveness of cancer stem cells but that also potentiates the anti-tumor effect of the standard chemotherapy with paclitaxel by a synergistic action leading to downregulation of cyclin B1.